IntelliCell BioSciences Announces It Will Present and Run Workshop at the 10th Annual Commercialization of Regenerative Medicine in London
NEW YORK, Nov. 14, 2012 /PRNewswire/ — IntelliCell BioSciences, Inc. (“Company”) (SVFC) announced today it will present at the Marcus Evans 10(th) Annual Commercialization of Regenerative Medicine in London, UK on the 28-30(th) November 2012. The Company will also be conducting a half-day pre-conference workshop addressing market entry strategies for emerging regenerative medicine companies.
IntelliCell’s EVP Clinical Development, Robert Sexauer, stated “Our Company is very pleased to be participating in this well established conference for emerging regenerative medicine technologies. Over the past several years, our management team has processed over 10,000 autologous cellular products and we are happy to share our insights regarding market entry strategies for emerging companies in our industry. We want to see the entire regenerative medicine industry continue to develop compliant processes, systems, and practices for better medicine”
Dr. Steven Victor, Chairman and CEO of IntelliCell stated “This is an exciting time for regenerative medicine companies. IntelliCell is taking a thought leadership role in the translation of technologies from the research laboratories and into clinical practice. Our objective is to continue to harmonize the requirements of regulators, clinicians, and patients receiving these profound new treatments.”
About IntelliCell BioSciences
IntelliCell BioSciences is a Regenerative Medicine company developing novel technologies that address the regenerative, curative, and preventative conditions of disease states with high unmet clinical needs. The Company has several patent pending applications including an industry unique method of obtaining autologous stromal vascular fraction cells (SVF) from the vasculature surrounding adipose tissue containing adult stem cells and a robust population of regenerative healing cells. The Company is also pioneering the development of autologous and allogeneic cells from living and non-living tissue donors for research purposes. IntelliCell is planning a series of in-human clinical studies with top tier universities for the treatment of osteoarthritis, multiple sclerosis, lower limb ischemic wounds, and gum regeneration in the oral cavity as well as medical aesthetics. The Company has developed a first in class cGTP cellular processing facility in New York City, purpose built and designed to be fully integrated into its ambulatory surgery center.
Certain statements set forth in this press release constitute “forward-looking statements.” Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain the words “estimate,” “project,” “intend,” “forecast,” “anticipate,” “plan,” “planning,” “expect,” “believe,” “will likely,” “will reach,” “will change,” “will soon,” “should,” “could,” “would,” “may,” “can” or words or expressions of similar meaning. Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the company’s actual results and financial position to differ materially from those included within the forward-looking statements. Forward-looking statements involve risks and uncertainties, including those relating to the Company’s ability to grow its business. Actual results may differ materially from the results predicted and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the Company’s limited operating history, the limited financial resources, domestic or global economic conditions, activities of competitors and the presence of new or additional competition, and changes in Federal or State laws. More information about the potential factors that could affect the Company’s business and financial results is included in the Company’s filings, available via the United States Securities and Exchange Commission.
IntelliCell BioSciences, Inc.
Email Contact: email@example.com
SOURCE IntelliCell BioSciences, Inc.